PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
45.87%
Growth of 45.87% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
-19.78%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive advantage potential.
67.35%
Growth of 67.35% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
14.73%
Margin change of 14.73% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
2902.62%
R&D growth while Drug Manufacturers - Specialty & Generic reduces spending. Peter Lynch would examine strategic differences.
26.30%
G&A change of 26.30% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
14.31%
Marketing expense change of 14.31% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
17.57%
Other expenses change of 17.57% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
29.73%
Operating expenses growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
17.71%
Total costs growth while Drug Manufacturers - Specialty & Generic reduces costs. Peter Lynch would examine differences.
-58.30%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
5.08%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.76%. Jim Chanos would check for overinvestment.
263.62%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.03%. Joel Greenblatt would investigate advantages.
147.43%
EBITDA margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.69%. Joel Greenblatt would investigate advantages.
1734.07%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.78%. Joel Greenblatt would investigate advantages.
1220.24%
Margin change of 1220.24% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-216.59%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.36%. Seth Klarman would investigate advantages.
1207.24%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.94%. Joel Greenblatt would investigate advantages.
796.18%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.43%. Joel Greenblatt would investigate advantages.
103.67%
Tax expense change of 103.67% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-29.67%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-51.78%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-43.13%
EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-35.00%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.